

Lubrizol to spotlight innovative polymer-based excipients at CPHI Frankfurt 2025

02 September 2025 | News

The company partners with pharmaceutical and nutraceutical developers worldwide to deliver innovative solutions that enhance patient outcomes and consumer experience



The company partners with pharmaceutical and nutraceutical developers worldwide to deliver innovative solutions that enhance patient outcomes and consumer experience

Lubrizol will showcase its advanced portfolio of polymer-based excipients designed to improve the solubility, bioavailability and palatability of APIs and nutraceuticals at CPHI Frankfurt 2025 (28th-30 October, Stand 8.0M71).

The company partners with pharmaceutical and nutraceutical developers worldwide to deliver innovative solutions that enhance patient outcomes and consumer experience. At CPHI, Lubrizol will highlight three of its flagship excipients:

Apisolex Polymer Excipient [®] a polyamino acid-based excipient for injectable and parenteral drug formulations. Apisolex can boost API solubility up to 50,000-fold, with additional benefits such as high drug loading and simplified formulation, offering potential for life-changing therapies.

Apinovex Polymer Excipient [®] designed to enhance solubility for BCS Class II and IV APIs in oral dosage forms. Apinovex enables up to a tenfold improvement in dissolution of crystalline APIs, stable amorphous solid dispersions, high drug loading (up to 80 per cent), and opportunities for innovative oral formats such as custom release profiles and multi-API tablets.

Carbopol Polymer Excipient [®] trusted for over six decades, Carbopol supports a wide range of pharmaceutical and nutraceutical applications, from oral tablets to topical creams. Benefits include improved delivery of active ingredients, taste-masking, high drug loading, enhanced tablet hardness, and superior stability. It also offers value for supplements such as gummies and chewables by improving bioavailability, taste, and dispersibility in liquids.

With these innovations, Lubrizol aims to provide formulators with best-in-class excipient technologies that meet complex formulation challenges, while improving patient adherence and consumer satisfaction.